Chembio Diagnostics - CEMI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.83
▼ -0.02 (-2.34%)

This chart shows the closing price for CEMI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chembio Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CEMI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CEMI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Chembio Diagnostics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.83.

This chart shows the closing price for CEMI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Chembio Diagnostics. This rating has held steady since November 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2022Colliers SecuritiesReiterated RatingNeutralMedium
7/21/2021Colliers SecuritiesDowngradeBuy ➝ NeutralHigh
3/11/2021Colliers SecuritiesReiterated RatingBuy$8.00Medium
12/3/2020Craig HallumUpgradeHold ➝ Buy$5.00 ➝ $10.00Low
11/6/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$7.50Low
6/17/2020Robert W. BairdDowngradeHold$4.00High
6/17/2020Colliers SecuritiesDowngradeBuy ➝ NeutralHigh
6/17/2020Craig HallumDowngradeBuy ➝ Hold$8.00High
6/17/2020BenchmarkDowngradeSpeculative Buy ➝ HoldHigh
5/26/2020Robert W. BairdInitiated CoverageOutperform$21.00High
4/23/2020Craig HallumBoost TargetBuy$15.00 ➝ $21.00Medium
4/1/2020BenchmarkBoost TargetSpeculative Buy$4.00 ➝ $7.00High
3/4/2020BenchmarkLower TargetSpeculative Buy$9.00 ➝ $5.00High
6/17/2019BenchmarkLower TargetBuy$14.00 ➝ $9.00High
12/19/2018Dougherty & CoInitiated CoverageBuy ➝ BuyMedium
7/11/2018BenchmarkInitiated CoverageBuy$14.00Low
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2022

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Chembio Diagnostics logo
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Read More

Today's Range

Now: $0.83
Low: $0.82
High: $0.86

50 Day Range

MA: $0.76
Low: $0.63
High: $1.10

52 Week Range

Now: $0.83
Low: $0.42
High: $3.38

Volume

1,043,890 shs

Average Volume

636,135 shs

Market Capitalization

$25.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Chembio Diagnostics?

The following equities research analysts have issued research reports on Chembio Diagnostics in the last twelve months: Colliers Securities, and StockNews.com.
View the latest analyst ratings for CEMI.

What is the current price target for Chembio Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Chembio Diagnostics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Chembio Diagnostics in the next year.
View the latest price targets for CEMI.

What is the current consensus analyst rating for Chembio Diagnostics?

Chembio Diagnostics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CEMI, but not buy more shares or sell existing shares.
View the latest ratings for CEMI.

What other companies compete with Chembio Diagnostics?

How do I contact Chembio Diagnostics' investor relations team?

Chembio Diagnostics' physical mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company's listed phone number is (631) 924-1135 and its investor relations email address is [email protected] The official website for Chembio Diagnostics is www.chembio.com. Learn More about contacing Chembio Diagnostics investor relations.